Wei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wei Wang has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Kirsty Stuart
Westmead Breast Cancer Institute, Westmead Hospital, Sydney, Australia
4 shared publications - Verity Ahern
Crown Princess Mary Cancer Centre Westmead Hospital Sydney New South Wales Australia
3 shared publications - Elisabeth Elder
Westmead Breast Cancer Institute, Westmead Hospital, Sydney, Australia
2 shared publications James French
General Surgery, Blacktown and Mount Druitt Hospitals Sydney New South Wales Australia
2 shared publications- Nicholas Ngui
General Surgery, Blacktown and Mount Druitt Hospitals Sydney New South Wales Australia
2 shared publications Simon Ashworth
Department of Radiation Oncology Crown Princess Mary Cancer Centre Westmead Hospital Sydney New South Wales Australia
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33 (6) , 1406-1418
Comparison of four breast lymphoedema patient reported outcome measures in women following breast conserving surgery and radiotherapy: examination of frequencies of symptoms and measurement properties
Background: Lymphoedema of the breast is a potential consequence of breast cancer treatment. Questionnaires exist to quantify breast symptoms but evidence for measurement properties is limited. This study aimed to evaluate measurement properties of breast lymphoedema questionnaires and report on frequency and severity of breast symptoms in women with breast cancer. Methods: Women following breast conserving surgery and radiotherapy were recruited. Four questionnaires, Breast Lymphoedema Severity Symptom questionnaire (BLYSS), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Breast Symptom Subscale (EORTC-QLQ-BSS), Lymphoedema Symptom Intensity and Distress scale–Trunk (LSIDS-T) and Breast Oedema Bother scale (BOB), were completed three and nine-months after radiotherapy. Measurement properties and breast symptoms were evaluated. Results: Questionnaires were completed by 164 women at three-months, and 152 at nine-months post radiotherapy. Internal consistency was strong for all questionnaires (McDonald’s Omega and Cronbach’s ⍺ ≥0.7). Correlation between BLYSS and EORTC-QLQ-BSS and BOB visual analogue scale (BOB-VAS) met the hypothesised level (r s ≥ 0.7) demonstrating construct validity. Exploratory factor analysis demonstrated single factors for individual tools and four factors when all four questionnaires were combined: pain, swelling, breast sensations and hardness. Responsiveness was high for BLYSS and moderate for EORTC-QLQ-BSS and BOB-VAS. Over half the women experienced symptoms ≥twice/week at mild-extreme severity. Breast pain, hardness, oversensitivity and swelling were most reported symptoms. Conclusion: The BLYSS demonstrated the strongest measurement properties among the PROMs evaluated with strong internal consistency, construct validity and responsiveness. Breast symptoms were commonly experienced by women after breast cancer treatment.
- 8 October 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33 (6) , 1406-1418
Open AccessComparison of four breast lymphoedema patient reported outcome measures in women following breast conserving surgery and radiotherapy: examination of frequencies of symptoms and measurement properties
Background: Lymphoedema of the breast is a potential consequence of breast cancer treatment. Questionnaires exist to quantify breast symptoms but evidence for measurement properties is limited. This study aimed to evaluate measurement properties of breast lymphoedema questionnaires and report on frequency and severity of breast symptoms in women with breast cancer. Methods: Women following breast conserving surgery and radiotherapy were recruited. Four questionnaires, Breast Lymphoedema Severity Symptom questionnaire (BLYSS), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Breast Symptom Subscale (EORTC-QLQ-BSS), Lymphoedema Symptom Intensity and Distress scale–Trunk (LSIDS-T) and Breast Oedema Bother scale (BOB), were completed three and nine-months after radiotherapy. Measurement properties and breast symptoms were evaluated. Results: Questionnaires were completed by 164 women at three-months, and 152 at nine-months post radiotherapy. Internal consistency was strong for all questionnaires (McDonald’s Omega and Cronbach’s ⍺ ≥0.7). Correlation between BLYSS and EORTC-QLQ-BSS and BOB visual analogue scale (BOB-VAS) met the hypothesised level (r s ≥ 0.7) demonstrating construct validity. Exploratory factor analysis demonstrated single factors for individual tools and four factors when all four questionnaires were combined: pain, swelling, breast sensations and hardness. Responsiveness was high for BLYSS and moderate for EORTC-QLQ-BSS and BOB-VAS. Over half the women experienced symptoms ≥twice/week at mild-extreme severity. Breast pain, hardness, oversensitivity and swelling were most reported symptoms. Conclusion: The BLYSS demonstrated the strongest measurement properties among the PROMs evaluated with strong internal consistency, construct validity and responsiveness. Breast symptoms were commonly experienced by women after breast cancer treatment.
- Open Access
- 26 July 2026
- Published by Wiley in Anz Journal of Surgery
Clinical Relevance of the SOUND and INSEMA Trials in Women With Early Breast Cancer in Australia and New Zealand
Background: Axillary surgery in breast cancer has undergone progressive de‐escalation. The recent Sentinel Node versus Observation after Axillary Ultrasound (SOUND) and Intergroup Sentinel Mamma (INSEMA) trials have demonstrated that sentinel lymph node biopsy may be safely omitted in selected patients. This study aimed to evaluate the clinical relevance and applicability of the SOUND and INSEMA trial criteria within the Australian and New Zealand context. Methods: Prospectively maintained data from the BreastSurgANZ Quality Audit (BQA) was analysed. Patients with invasive breast cancer treated between 2019 and 2023 who met the inclusion criteria of the SOUND and INSEMA trials were identified. Results: A total of 69 122 patients were treated for invasive breast cancer over the five‐year study period, of whom 30 822 fulfilled the inclusion criteria of either the SOUND or INSEMA trials. Overall, 34.0% and 44.6% of patients with invasive breast cancer in Australia and New Zealand met the SOUND and INSEMA eligibility criteria, respectively. Tumour characteristics of BQA patients were more closely aligned with those reported in the SOUND trial than the INSEMA trial, although key differences in other clinicopathological features were observed. Conclusions: The SOUND and INSEMA trial criteria are applicable to over one‐third of patients with invasive breast cancer in Australia and New Zealand, supporting the potential relevance of axillary surgery de‐escalation in this population.
- 26 July 2026
- Published by Wiley in Anz Journal of Surgery
Open AccessClinical Relevance of the SOUND and INSEMA Trials in Women With Early Breast Cancer in Australia and New Zealand
Background: Axillary surgery in breast cancer has undergone progressive de‐escalation. The recent Sentinel Node versus Observation after Axillary Ultrasound (SOUND) and Intergroup Sentinel Mamma (INSEMA) trials have demonstrated that sentinel lymph node biopsy may be safely omitted in selected patients. This study aimed to evaluate the clinical relevance and applicability of the SOUND and INSEMA trial criteria within the Australian and New Zealand context. Methods: Prospectively maintained data from the BreastSurgANZ Quality Audit (BQA) was analysed. Patients with invasive breast cancer treated between 2019 and 2023 who met the inclusion criteria of the SOUND and INSEMA trials were identified. Results: A total of 69 122 patients were treated for invasive breast cancer over the five‐year study period, of whom 30 822 fulfilled the inclusion criteria of either the SOUND or INSEMA trials. Overall, 34.0% and 44.6% of patients with invasive breast cancer in Australia and New Zealand met the SOUND and INSEMA eligibility criteria, respectively. Tumour characteristics of BQA patients were more closely aligned with those reported in the SOUND trial than the INSEMA trial, although key differences in other clinicopathological features were observed. Conclusions: The SOUND and INSEMA trial criteria are applicable to over one‐third of patients with invasive breast cancer in Australia and New Zealand, supporting the potential relevance of axillary surgery de‐escalation in this population.
- 7 April 2024
- Published by Elsevier in Medical Dosimetry
- Vol. 49 (4) , 307-313
DIBH reduces right coronary artery and lung radiation dose in right breast cancer loco-regional radiotherapy
- 7 April 2024
- Published by Elsevier in Medical Dosimetry
- Vol. 49 (4) , 307-313
DIBH reduces right coronary artery and lung radiation dose in right breast cancer loco-regional radiotherapy
- Open Access
- 22 February 2024
- Published by Springer Nature in Journal of Cancer Education
- Vol. 39 (3) , 279-287
The Development and Evaluation of an Educational Video for Breast Cancer Patients Requiring Adjuvant Radiation Therapy
Patient education and informed consent are required prior to adjuvant radiation therapy (RT) for early breast cancer (EBC), and include the role, rationale, potential toxicities and practicalities of the treatment process. Current education of patients about RT is verbal, in the form of a consultation by a radiation oncologist, often supplemented with print or online materials. This approach is limited by its doctor-dependency and non-standardised nature. Video education is being recognised increasingly as an opportunity to remediate this and appeal to patients’ preference for visual learning. The purpose of this study was to design and produce a video as an educational adjunct for EBC patients’ viewing prior to adjuvant RT, and to evaluate its acceptability through content analysis of three online focus group discussions, among ten participants with EBC requiring RT. After qualitative content analysis of the focus group transcripts, data were summarised into three main categories: (1) understanding of RT, (2) ease of engagement with the video and (3) anxiety and preparedness for RT. The 18-min video was positively received by all participants, and discussion feedback was used to inform improvements to the video. This focus group study demonstrated that the video was well understood, informative and acceptable to EBC patients in preparing them for RT. The effectiveness of the video in improving knowledge and alleviating distress in preparation for therapy will be further evaluated in an ethics-approved biphasic quasi-experimental study.
- 22 February 2024
- Published by Springer Nature in Journal of Cancer Education
- Vol. 39 (3) , 279-287
Open AccessThe Development and Evaluation of an Educational Video for Breast Cancer Patients Requiring Adjuvant Radiation Therapy
Patient education and informed consent are required prior to adjuvant radiation therapy (RT) for early breast cancer (EBC), and include the role, rationale, potential toxicities and practicalities of the treatment process. Current education of patients about RT is verbal, in the form of a consultation by a radiation oncologist, often supplemented with print or online materials. This approach is limited by its doctor-dependency and non-standardised nature. Video education is being recognised increasingly as an opportunity to remediate this and appeal to patients’ preference for visual learning. The purpose of this study was to design and produce a video as an educational adjunct for EBC patients’ viewing prior to adjuvant RT, and to evaluate its acceptability through content analysis of three online focus group discussions, among ten participants with EBC requiring RT. After qualitative content analysis of the focus group transcripts, data were summarised into three main categories: (1) understanding of RT, (2) ease of engagement with the video and (3) anxiety and preparedness for RT. The 18-min video was positively received by all participants, and discussion feedback was used to inform improvements to the video. This focus group study demonstrated that the video was well understood, informative and acceptable to EBC patients in preparing them for RT. The effectiveness of the video in improving knowledge and alleviating distress in preparation for therapy will be further evaluated in an ethics-approved biphasic quasi-experimental study.
- 8 September 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (10) , 1-18
Experiences of breast cancer survivors with exercise rehabilitation: qualitative systematic review and meta-synthesis
Purpose This study aimed to synthesize and evaluate the available qualitative literature on posttreatment participation in exercise rehabilitation among breast cancer survivors. Methods This systematic review followed the Joanna Briggs Institute (JBI) meta-aggregation approach guided by ENTREQ, graded according to the ConQual approach, and evaluated using the JBI Qualitative Assessment and Review Instrument (JBI-QARI). We searched qualitative or mixed methods studies related to the experiences of exercise rehabilitation among breast cancer survivors conducted until April 13, 2023, in nine English and Chinese databases. The selected studies were reviewed independently, and the data were collaboratively synthesized into core themes. Results A total of 24 studies were included, and 88 findings resulted in five synthesis findings: (a) benefits of participating in exercise rehabilitation, (b) facilitators of participation in exercise rehabilitation, (c) obstacle factors for participating in exercise rehabilitation, (d) evaluation of the exercise program, and (e) recommendations. Conclusion Breast cancer survivors need exercise to recover physically and mentally and to transition from cancer treatment to a normal life. The factors affecting exercise participation in breast cancer survivors are complex. Breast cancer survivors require timely and continuous effective exercise intervention forms, including online, offline, instrumental, and emotional support from others, especially healthcare providers and family members. Moreover, multidisciplinary collaboration is required to develop more effective and convenient exercise interventions.
- 8 September 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (10) , 1-18
Experiences of breast cancer survivors with exercise rehabilitation: qualitative systematic review and meta-synthesis
Purpose This study aimed to synthesize and evaluate the available qualitative literature on posttreatment participation in exercise rehabilitation among breast cancer survivors. Methods This systematic review followed the Joanna Briggs Institute (JBI) meta-aggregation approach guided by ENTREQ, graded according to the ConQual approach, and evaluated using the JBI Qualitative Assessment and Review Instrument (JBI-QARI). We searched qualitative or mixed methods studies related to the experiences of exercise rehabilitation among breast cancer survivors conducted until April 13, 2023, in nine English and Chinese databases. The selected studies were reviewed independently, and the data were collaboratively synthesized into core themes. Results A total of 24 studies were included, and 88 findings resulted in five synthesis findings: (a) benefits of participating in exercise rehabilitation, (b) facilitators of participation in exercise rehabilitation, (c) obstacle factors for participating in exercise rehabilitation, (d) evaluation of the exercise program, and (e) recommendations. Conclusion Breast cancer survivors need exercise to recover physically and mentally and to transition from cancer treatment to a normal life. The factors affecting exercise participation in breast cancer survivors are complex. Breast cancer survivors require timely and continuous effective exercise intervention forms, including online, offline, instrumental, and emotional support from others, especially healthcare providers and family members. Moreover, multidisciplinary collaboration is required to develop more effective and convenient exercise interventions.
- Open Access
Role of Functional MRI in Liver SBRT: Current Use and Future Directions
Stereotactic body radiation therapy (SBRT) is an emerging treatment for liver cancers whereby large doses of radiation can be delivered precisely to target lesions in 3–5 fractions. The target dose is limited by the dose that can be safely delivered to the non-tumour liver, which depends on the baseline liver functional reserve. Current liver SBRT guidelines assume uniform liver function in the non-tumour liver. However, the assumption of uniform liver function is false in liver disease due to the presence of cirrhosis, damage due to previous chemo- or ablative therapies or irradiation, and fatty liver disease. Anatomical information from magnetic resonance imaging (MRI) is increasingly being used for SBRT planning. While its current use is limited to the identification of target location and size, functional MRI techniques also offer the ability to quantify and spatially map liver tissue microstructure and function. This review summarises and discusses the advantages offered by functional MRI methods for SBRT treatment planning and the potential for adaptive SBRT workflows.
Open AccessRole of Functional MRI in Liver SBRT: Current Use and Future Directions
Stereotactic body radiation therapy (SBRT) is an emerging treatment for liver cancers whereby large doses of radiation can be delivered precisely to target lesions in 3–5 fractions. The target dose is limited by the dose that can be safely delivered to the non-tumour liver, which depends on the baseline liver functional reserve. Current liver SBRT guidelines assume uniform liver function in the non-tumour liver. However, the assumption of uniform liver function is false in liver disease due to the presence of cirrhosis, damage due to previous chemo- or ablative therapies or irradiation, and fatty liver disease. Anatomical information from magnetic resonance imaging (MRI) is increasingly being used for SBRT planning. While its current use is limited to the identification of target location and size, functional MRI techniques also offer the ability to quantify and spatially map liver tissue microstructure and function. This review summarises and discusses the advantages offered by functional MRI methods for SBRT treatment planning and the potential for adaptive SBRT workflows.
- Open Access
- 21 January 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 10 (3) , 1093-1098
Epibulbar osseous choristoma: Two case reports
Choristoma is a rare, benign, congenital proliferative tumor, with osseous choristoma being the rarest. Although the tumor is benign, effective identification is needed for its diagnosis and treatment. Here, we report the diagnosis and successful surgical treatment of two patients with osseous choristoma. Two patients, a young female and young male patient, were found to have a mass on the ocular surface. The tumor presented on the superior temporal bulbar conjunctiva in the first patient and on the upper eyelid in the second patient. Ultrasound biomicroscopy detected a strong echo with clear boundaries covering the lower echo, and computed tomography examination revealed calcification. Both patients underwent surgery, and histopathological evaluation of the mass showed osseous choristoma. They were treated by excision and subsequently cured. Osseous choristomas are usually asymptomatic. Our patients were cured immediately after surgery, suggesting that surgical treatment is an effective strategy.
- 21 January 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 10 (3) , 1093-1098
Open AccessEpibulbar osseous choristoma: Two case reports
Choristoma is a rare, benign, congenital proliferative tumor, with osseous choristoma being the rarest. Although the tumor is benign, effective identification is needed for its diagnosis and treatment. Here, we report the diagnosis and successful surgical treatment of two patients with osseous choristoma. Two patients, a young female and young male patient, were found to have a mass on the ocular surface. The tumor presented on the superior temporal bulbar conjunctiva in the first patient and on the upper eyelid in the second patient. Ultrasound biomicroscopy detected a strong echo with clear boundaries covering the lower echo, and computed tomography examination revealed calcification. Both patients underwent surgery, and histopathological evaluation of the mass showed osseous choristoma. They were treated by excision and subsequently cured. Osseous choristomas are usually asymptomatic. Our patients were cured immediately after surgery, suggesting that surgical treatment is an effective strategy.
- 24 August 2021
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 65 (7) , 951-955
Feasibility of arm‐draining lymph node‐sparing radiotherapy of breast cancer: A pilot planning study
Introduction Lymphoedema following axillary radiotherapy for breast cancer causes significant morbidity. Our goal was to evaluate the feasibility of sparing the lymph node that drains the arm’s lymphatics (ARM node) while achieving standard dose constraints for whole breast and comprehensive lymph node irradiation. Methods Six patients underwent lymphoscintigraphy and SPECT CT to identify the breast sentinel node (SN) and ARM node. The ARM node was contoured on the SPECT CT and deformably registered to the radiotherapy treatment planning CT. Radiotherapy plans (50 Gy in 25 fractions) with VMAT technique were generated, with the aim to spare the ARM node (Mean dose 47.5 Gy, and axillary nodal CTV excluding ARM node to achieve D90% > 45 Gy. Results In one patient, the ARM node was within the volume of breast SN site and sparing was not possible. For the remaining 5 patients, an ARM node-sparing plan could be successfully generated; the mean dose to the ARM node ranged from 11.2 to 23.1 Gy (median 13.8 Gy). In these 5 subjects, D90% > 45 Gy of axillary nodal CTV (range, 44.9–48.5 Gy, median 46.2 Gy) and D98% > 47.5 Gy of breast SN site were achieved. Conclusion In this planning study, ARM node-sparing VMAT of the breast and lymph nodes was feasible, while maintaining adequate dosimetric coverage. However, in some individuals, localization of the ARM node in close proximity to breast SN site precluded the generation of an ARM node-sparing treatment plan.
- 24 August 2021
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 65 (7) , 951-955
Feasibility of arm‐draining lymph node‐sparing radiotherapy of breast cancer: A pilot planning study
Introduction Lymphoedema following axillary radiotherapy for breast cancer causes significant morbidity. Our goal was to evaluate the feasibility of sparing the lymph node that drains the arm’s lymphatics (ARM node) while achieving standard dose constraints for whole breast and comprehensive lymph node irradiation. Methods Six patients underwent lymphoscintigraphy and SPECT CT to identify the breast sentinel node (SN) and ARM node. The ARM node was contoured on the SPECT CT and deformably registered to the radiotherapy treatment planning CT. Radiotherapy plans (50 Gy in 25 fractions) with VMAT technique were generated, with the aim to spare the ARM node (Mean dose 47.5 Gy, and axillary nodal CTV excluding ARM node to achieve D90% > 45 Gy. Results In one patient, the ARM node was within the volume of breast SN site and sparing was not possible. For the remaining 5 patients, an ARM node-sparing plan could be successfully generated; the mean dose to the ARM node ranged from 11.2 to 23.1 Gy (median 13.8 Gy). In these 5 subjects, D90% > 45 Gy of axillary nodal CTV (range, 44.9–48.5 Gy, median 46.2 Gy) and D98% > 47.5 Gy of breast SN site were achieved. Conclusion In this planning study, ARM node-sparing VMAT of the breast and lymph nodes was feasible, while maintaining adequate dosimetric coverage. However, in some individuals, localization of the ARM node in close proximity to breast SN site precluded the generation of an ARM node-sparing treatment plan.
- Open Access
- 14 August 2021
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 30, 95-99
Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
- 14 August 2021
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 30, 95-99
Open AccessPhase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
- Open Access
- 9 April 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 456
Factors Influencing the Incidental Dose Distribution in Internal Mammary Nodes: A Comparative Study
Objective: To investigate the effect of anatomic and technical parameters on the incidental internal mammary lymph node (IMN) irradiation (IIMNI) dose among postmastectomy patients. Methods: We retrospectively delineated the IMN on planning CT images from 138 patients who had undergone postmastectomy radiotherapy (PMRT). We analyzed the IIMNI dose coverage and its relationship with anatomic and technical parameters. Results: The IIMNI mean dose was 32.85 ± 9.49 Gy, and 10 of 138 patients (7.25%) treated with PMRT received ≥45 Gy. In univariate analysis, the body weight, body mass index, body surface area, thoracic transverse diameter (DT), ratio of DT to the thoracic anteroposterior diameter (DAP)(RT/AP), planning target volume of IMN (PTVIMN) included in PTV (IMNin) and the ratio of IMNin to PTVIMN (RIMNin) and PTV posterior border were the parameters affecting IIMNI dose. In multivariate analysis, body weight, RT/AP, and RIMNin were correlative factors that affected IIMNI dose. Conclusions: For patients who underwent PMRT without IMN irradiation (IMNI), there was a wide variety in IIMNI doses. A minority of patients had adequate IIMNI dose coverage, and the higher IIMNI doses were associated with the less body weights and more RIMNin.
- 9 April 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 456
Open AccessFactors Influencing the Incidental Dose Distribution in Internal Mammary Nodes: A Comparative Study
Objective: To investigate the effect of anatomic and technical parameters on the incidental internal mammary lymph node (IMN) irradiation (IIMNI) dose among postmastectomy patients. Methods: We retrospectively delineated the IMN on planning CT images from 138 patients who had undergone postmastectomy radiotherapy (PMRT). We analyzed the IIMNI dose coverage and its relationship with anatomic and technical parameters. Results: The IIMNI mean dose was 32.85 ± 9.49 Gy, and 10 of 138 patients (7.25%) treated with PMRT received ≥45 Gy. In univariate analysis, the body weight, body mass index, body surface area, thoracic transverse diameter (DT), ratio of DT to the thoracic anteroposterior diameter (DAP)(RT/AP), planning target volume of IMN (PTVIMN) included in PTV (IMNin) and the ratio of IMNin to PTVIMN (RIMNin) and PTV posterior border were the parameters affecting IIMNI dose. In multivariate analysis, body weight, RT/AP, and RIMNin were correlative factors that affected IIMNI dose. Conclusions: For patients who underwent PMRT without IMN irradiation (IMNI), there was a wide variety in IIMNI doses. A minority of patients had adequate IIMNI dose coverage, and the higher IIMNI doses were associated with the less body weights and more RIMNin.